Washington University
The high-coverage whole-genome assay is covered for patients with myeloid neoplasms, including acute myeloid leukemia and myelodysplastic syndrome.
By using a bright fluorescent particle, the researchers were able to achieve between 95 and 96 percent sensitivity for their SARS-CoV-2 tests.
The test measures changes in wavelength to quantify the presence of disease in a patient sample in about 40 minutes.
New Biomarker, Test From Wash U Team Aims to ID Patients at Higher Risk of Cardiovascular Disease
Premium
The diagnostic blood test for elevated serum fatty acid synthase detected patients at risk of chronic limb-threatening ischemia with 83 percent accuracy.
Genetic Technologies, WashU Team up to Study Breast Cancer Risk in Woman of African Descent
The Australian company is working with the Institute for Public Health in St. Louis to expand the predictive capability of its GeneType breast cancer risk test.
Jul 14, 2021
Jun 14, 2019
Jul 18, 2018
Nov 9, 2017